Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: A New CEO at Quanterix; VP at Biodesix; and More


Quanterix announced this week it has appointed Paul Chapman as its new president and CEO, replacing Martin Madaus, who will continue at the company as executive chairman.

Chapman was previously vice president of EMD Millipore's BioPharm Processing Solutions business. Before that he was vice president of hospital solutions for Roche Near Patient Testing in Austria.

Biodesix this week appointed Dominic Spinella vice president of clinical development and medical affairs.

Spinella was previously executive director and head of translational and molecular medicine for Pfizer's biotherapeutics division. Prior to that he was head of translational medicine for Pfizer Oncology as well as vice president of exploratory research at Chugai Pharmaceuticals.

Opko Health has appointed Juan Rodriguez as senior vice president and chief financial officer.

Rodriguez was previously a consultant to software firm Cognitec Systems. Before that he held a number of executive positions at Kos Pharmaceuticals, which was acquired in 2007 by Abbott Laboratories.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.